FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

por Gaibar, María, Novillo, Apolonia, Romero-Lorca, Alicia, Malón, Diego, Antón, Beatriz, Moreno, Amalia, Fernández-Santander, Ana
Publicado 2022

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

por Novillo, Apolonia, Gaibar, María, Romero-Lorca, Alicia, Malón, Diego, Antón, Beatriz, Moreno, Amalia, Fernández-Santander, Ana
Publicado 2023

Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

por Gaibar, María, Galán, Miguel, Romero-Lorca, Alicia, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana, Novillo, Apolonia
Publicado 2021

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

por Quintela-Fandino, Miguel, Apala, Juan V., Malon, Diego, Mouron, Silvana, Hornedo, Javier, Gonzalez-Cortijo, Lucia, Colomer, Ramon, Guerra, Juan
Publicado 2019

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

por Novillo, Apolonia, Gaibar, María, Romero-Lorca, Alicia, Gilsanz, María Fuencisla, Beltrán, Laura, Galán, Miguel, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana
Publicado 2020

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

por Romero-Lorca, Alicia, Novillo, Apolonia, Gaibar, María, Gilsanz, María Fuencisla, Galán, Miguel, Beltrán, Laura, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana
Publicado 2021

p27(Kip1) V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer

por Mouron, Silvana, Bueno, Maria J, Muñoz, Manuel, Torres, Raul, Rodríguez, Sandra, Apala, Juan V, Silva, Jorge, Sánchez-Bayona, Rodrigo, Manso, Luis, Guerra, Juan, Rodriguez-Lajusticia, Laura, Malon, Diego, Malumbres, Marcos, Quintela-Fandino, Miguel
Publicado 2023

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

por Quintela-Fandino, Miguel, Holgado, Esther, Manso, Luis, Morales, Serafin, Bermejo, Begoña, Colomer, Ramon, Apala, Juan V., Blanco, Raquel, Muñoz, Manuel, Caleiras, Eduardo, Iranzo, Vega, Martinez, Mario, Dominguez, Orlando, Hornedo, Javier, Gonzalez-Cortijo, Lucia, Cortes, Javier, Gasol Cudos, Ariadna, Malon, Diego, Lopez-Alonso, Antonio, Moreno-Ortíz, María C., Mouron, Silvana, Mañes, Santos
Publicado 2020

Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

por Manso, Luis, Hernando, Cristina, Galán, María, Oliveira, Mafalda, Cabrera, Miguel A., Bratos, Raquel, Rodríguez, César A., Ruiz-Borrego, Manuel, Blanch, Salvador, Llombart-Cussac, Antonio, Delgado-Mingorance, Juan I., Álvarez-Busto, Iñaki, Gallegos, Isabel, González-Cortijo, Lucía, Morales, Serafín, Aguirre, Elena, Hernando, Blanca A., Ballesteros, Ana, Alés-Martínez, José E., Reboredo, Cristina, Oltra, Amparo, González-Cao, María, Santisteban, Marta, Malón, Diego, Echeverría, Isabel, García-Garre, Elisa, Vega, Estela, Servitja, Sònia, Andrés, Raquel, Robles, Carlos E., López, Rafael, Galve, Elena, Echarri, María J., Legeren, Marta, Moreno, Fernando
Publicado 2020